ABSTRACT. Localization of metallothionein (MT) -I & -II and MT-III and its significance in the brain aging in dogs were examined using immunohistological and molecular pathological techniques. MT-I & -II immunohistochemistry showed positive staining in the hypertrophic astrocytes throughout the aged dog brains; these MT-I & -II immunoreactive astrocytes were predominant in the cerebral cortex and around the blood vessels in the brain. These findings dominated in the brain regions with severe age-related morphological changes. In situ hybridization using MT-I mRNA riboprobes also demonstrated signals for MT-I mRNA in these hypertrophic astrocytes. Immunohistochemistry using a guinea pig antiserum against a synthetic polypeptide of canine MT-III demonstrated positive MT-III immunoreactivity predominantly in neurons in the Zn-rich regions such as hippocampus and parahippocampus. The findings were supported by in situ hybridization using MT-III mRNA riboprobes. Both MT-III immunoreactivity and signals for MT-III mRNA were demonstrated in neurons in the brain regardless of the intensity of the age-related changes. These results suggest, first, MT-I & -II may be induced in relation to the progress of the age-related morphological changes in the brain, playing an important role in the protection of the brain tissue from the toxic insults responsible for the brain aging, and second, MT-III may play a role in maintenance of Zn-related essential functions of the brain.-KEY WORDS: aging, brain, canine, in situ hybridization, metallothionein.
the recent discovery of the brain-specific MT-III, which inhibits neuron survival in vitro, the implications of MTs in the brain pathophysiology are strengthened [29] . MT-III mRNA may or may not be down regulated in patients with Alzheimer's disease (AD) [5, 29] . There is also a controversy as to the localization of MT-III in the brain. MT-III immunoreactivity was localized predominantly in astrocytes of the human and rat brains [1, 30, 31] . On the other hand, MT-III mRNA was demonstrated exclusively in neurons of mouse brain [12] . Thus, precise localization as well as physiological roles of MTs in the brain are yet to be determined.
We have previously reported the age-related morphological changes in the brain of dogs [22, 23] . In an attempt to better understand the pathophysiological roles of MTs, we studied the localization of MT-I & -II and MT-III in both protein and mRNA levels in the brain of aged dogs.
MATERIALS AND METHODS

Animals:
Ten aged dogs, five males and five females, ranging in age from 12 to 18 years were used in the present study (Table 1) . Three young beagle dogs ranging in age from 6 to 9 months were used as controls. The animals were killed by euthanasia or died of a variety of disorders including heart failure, tumor and renal failure. No signs of neurological disorders were observed in these dogs.
Histopathology: Brains were taken immediately after death and fixed in 10% phosphate-buffered formalin for three days. Brain samples at the level of frontal lobe, occipital lobe, corpus striatum and diencephalon were trimmed and embedded in paraffin wax. Serial sections cut Metallothioneins (MTs) are a family of low molecular weight (6,800 Da), cysteine-rich, metal-binding proteins that are found ubiquitously in a wide variety of species [9] . MTs are believed to play important roles in the homeostasis of essential metals including zinc and copper, in the detoxification of heavy metals, and in the scavenging of free radicals [4, 8] . Mammalian MT family consists of four similar but distinct isoforms, designated MT-I, -II, -III and -IV [16, 19] . MT-I and MT-II are believed to be essentially the same because both proteins show high homology (93.4% identity) in amino acid sequence and share expression pattern; both MT-I and MT-II genes are expressed in various organs including liver, kidney and brain, while MT-III is expressed only in the brain [16] . The brain specific MT-III contains 7 additional amino acids as compared to 61 amino acids for MT-I & -II isoforms [16] . In comparison with MT-I & -II, the genes of which are readily induced by heavy metals, MT-III do not show quick expression by these metals both in vivo and in vitro, suggesting MT-III is different from the other MT isotypes [5] . The expression of MT-IV is restricted to cornified and stratified squamous epithelium of skin, tongue, and upper alimentary tract [19] .
Immunohistochemical localization of MT-I & -II in the brain has been reported in humans [3, 27, 28] , monkeys [26] , mice [12, 14] and rats [14, 32] ; MT-I & -II were shown in choroid plexus epithelial cells, ependymal cells, pia mater, and astrocytes in the hypothalamus, hippocampus, cerebral cortex and white matter throughout the brain. With at 5 µm were stained with hematoxylin and eosin (HE) and periodic acid methenamine silver (PAM).
Generation and characterization of the polyclonal anti canine MT-III antibody: We selected amino acids sequence (51-63: Cys-Lys-Gly-Gly-Glu-Gly-Thr-Glu-Ala-Glu-AlaGlu-Lys) of the canine MT-III protein for generation of the polyclonal antibody; the residue contained six amino acid insertion, which is unique to the canine MT-III [10] . The polypeptide specific to canine MT-III was synthesized and conjugated at COOH-terminus SH group to keyhole limpet hemocyanine (Bio-Synthesis Inc., Texas, U.S.A.). After preimmune serum was collected, Hartley guinea pigs were given subcutaneous injection of 500 µg of keyhole limpet hemocyanine-peptide/50% Freund's complete adjuvant. The animals received three to four additional boosts at approximately 2 week intervals, consisting of 500 µg of the same adjuvant. Sera were collected after the immunizations. The specificity of the polyclonal anti canine MT-III antibody was determined by western blotting of total protein extracts from frozen tissues including the liver, kidney and brain, respectively [13] . Briefly, the proteins were electrophoresed on 15% sodium dodecyl sulfate polyacrylamide gel under reducing conditions, and electroblotted to clear blot P membrane (ATTO, Tokyo, Japan). The membrane was blocked with 5% skim milk in Tris-buffer and incubated with anti canine MT-III antibody (1:200). The membrane was then, reacted with biotinylated antisera against guinea pig immunoglobulin (1:200, Funakoshi, Tokyo, Japan). The bound immunoglobulin was visualized with 3,3-diaminobenzidine. The specificity of the MT-III polyclonal antibody was tested by the preabsorption techniques in which the antibody was preabsorbed with an excess amount (100 mM) of the initial antigen (MT-III specific synthetic polypeptide, Cys-Lys-Gly-Gly-Glu-Gly-Thr-Glu-Ala-GluAla-Glu-Lys).
Immunohistochemistry: The primary antibodies used in this study were MT-III polyclonal antibody against canine MT-III and monoclonal antibody against horse MT-I & -II (E9; Dako, Glostrup, Denmark). The monoclonal MT-I & -II antibody is specifically reactive with a conserved epitope of first five amino acid residues of the N-terminal portion of the molecule; the epitope is common to several mammalian species of MT [7] . Using the antibody, we h a v e r e p o r t e d a p a r t o f f i n d i n g s o f M Timmunohistochemistry in the brain of dogs under physiological and pathological conditions [21, 24, 25] . Monoclonal antibody to glial fibrillary acidic protein (GFAP) (Dako) was used to identify hypertrophic astrocytes [17] .
After blocking endogeneous peroxidase activity with 3% H 2 O 2 , sections were treated with 10% normal bovine serum, incubated with primary antibodies overnight at 4°C and then sequentially incubated with biotinylated goat anti mouse IgG (Dako) (1: 400) for the monoclonal antibodies and with biotinylated goat anti guinea pig IgG (Funakoshi) (1: 200) for the polyclonal antibody for 30 min at room temperature, and in peroxidase-conjugated streptavidin (Dako) for 30 min. Primary antibodies were diluted with PBS (1: 200 for MT-III; 1:400 for MT-I & -II; 1:400 for GFAP). After the first and second incubations, the sections were given three 5 min washes in phosphate-buffered saline (PBS) and then developed with 3,3-diaminobenzidine tetrahydrochloride and H 2 O 2 . The sections were counterstained with methyl green. The specificity of the MT-III polyclonal antibody was tested by preabsorption techniques in which the antibody was preabsorbed with an excess amount (100 mM) of the initial antigen. GFAP, MT-I & -II and MT-III immunopositive cells were determined by light microscopy at × 200 magnification. For each slide, 5 randomly selected fields were examined. The mean value per one field was calculated from the total number of immunopositive cells in each slide. Their incidence was graded from (-) to (+++) :
: 0/field, ±: 1-10/field, +: 11-20/field, ++: 21-30/field and +++ 31/field. In situ hybridization: Riboprobes were prepared from MT-I and -III cDNA constructs in pGEM-T Easy vector (Promega, Madison, U.S.A.). The MT-I construct contains 109 base pair (bp) of the COOH-terminus non coding region (184 bp through 293 bp) of the canine MT-I cDNA [10] . The MT-III construct contains 110 bp of the COOHterminus non coding region (291 bp through 401 bp) of canine MT-III cDNA [11] . Homology between the MT-I and -III probe is 25%. Digoxigenin-labeled riboprobes were synthesized by in vitro transcription from the linearized cDNA templates using the appropriate RNA polymerase (SP6/T7) according to the manufacture's protocol (Boehringer Mannheim, Mannheim, Germany). These riboprobes were used for in situ hybridization. Coronal paraffin sections (5 µm) cut at a level of diencephalon were used. Hybridization method used was reported before [11] . Briefly, after hybridization, the parafilm was dislodged by washing with 5 × SSC (1 × SSC = 0.15 M NaCl, 0.015 M Sodium citrate) and with 50% formamide, 2 × SSC for 60 min at 50°C, followed by two 10-min-washings at 50°C with 0.1 × SDS, 0.1 × SSC, 50% formamide. The slides were then incubated with alkaline-phosphatase-conjugated anti-digoxigenin antibody (Boehringer Mannheim). Following washing in Tris buffer nitroblue tetrazolium, development solution was applied in accordance with the manufacturer's protocol and the slides were placed in a dark, humid chamber. After color reaction, the slides were rinsed with 10 mM Tris-HCl (pH 8.0), 1 mM EDTA and mounted with counterstaining by methyl green.
RESULTS
Western blotting analysis:
Western blotting of the brain, liver and kidney using anti canine MT-III antibody revealed a single band exclusively in the lane of brain at approximately 6 kDa that corresponded in size to the reported molecular size of MTs [16, 19] (Fig. 1) . No band was shown in the lane of the liver and kidney, indicating the antibody obtained is specific to MT-III. The absorption of the polyclonal anti canine MT-III antibody with initial antigen abolished the positive band.
Histological and Immunohistochemical findings: Gross and microscopic examinations of the brain of the aged dogs revealed no signs of neurological disorders other than typical aged changes, such as thickening of the meninges, mild dilation of the ventricles, lipofuscin deposits in nerve cell bodies, neuronal loss, diffuse gliosis, occasional dystrophic axons and senile plaques.
Results of the immunohistochemical study on GFAP, MT-I & -II and MT-III were summarized in Table 2 . An increase in GFAP positive astrocytes in the aged dogs, as compared to controls, was the most consistent histological feature observed in the GFAP immunohistochemistry. These GFAP immunoreactive astrocytes were seen in the cerebral cortical layer from III to V, subpial area, white matter and periventricular area in the diencephalon (Fig. 2A) . In control dogs, there were a few GFAP immunoreactive astrocytes (Fig. 2B) . MT-I & -II immunoreactivity was shown in both nucleus and cytoplasm of astrocytes, which distributed in the thalamus, white matter, hippocampus, periventricular area and cerebral cortical layer from III to V; the finding was remarkable around the blood vessels of each regions (Fig. 3A) . The intensity of the MT-I & -II immunostaining was stronger in the brain regions with severe age-related morphological changes. A small number of MT-I & -II immunoreactive astrocytes were observed in the brain of control dogs (Fig. 3B) .
MT-III immunoreactivity was shown exclusively in nerve cell bodies in all dogs examined. The intensity of the immunoreactivity differed from case to case and from region to region in the brain. However, MT-III immunoreactive neurons were consistently demonstrated in the hippocampus CA1 and CA2 regions; the intensity was stronger in the CA1 than CA2 (data not shown). Consistent immunoreactivity was also shown in large neurons of parahippocampus and thalamic nuclei including nucleus anterior thalami, nucleus reticularis thalami and nucleus ventralis anterior in all dogs examined; neurons in the nucleus ventralis anterior showed strongest immunoreactivity (Fig. 4) . There was no MT-III immunolabelling in the other cell types including astrocyte, oligodendrocyte and microglia. The absorption of the anti canine MT-III antibody with the initial antigen abolished all staining. There was no staining observed when the anti canine MT-III antibody was omitted from the procedure. In situ hybridization: Canine MT-I mRNA was demonstrated predominantly in astrocytes throughout the brain, especially in those in the cerebral cortex (Fig. 3A) . Canine MT-III mRNA was shown exclusively in the nerve 
DISCUSSION
Aged dog brain shows a variety of age-related morphological changes including atrophy, signs of neuronal loss, axonal dystrophy, β-amyloidosis and astrocytic gliosis: these changes are very similar to those observed in the brain of aged humans [22, 23] . In the present study, GFAPpositive astrocytic gliosis was demonstrated in all the aged dog brain. The change is believed to be a reaction to the loss of neurons and dendrites [2, 20] . Astrocytes are shown to produce trophic factors, playing important roles in the regulation of the microenvironment in the brain [6, 18] . The possibility exists that astrocytic hypertrophy represents a primary effect of aging rather than a mere secondary response to degenerative events in the brain [15] .
MT-I & -II immunoreactivity was shown in astrocytes, ependymal cells and choroid plexus epithelial cells in the brain of dogs. The findings agreed with those reported in the brain of humans [3, 27, 28] , monkeys [26] , rats [14, 32] and mice [12, 14] . Intense MT-I & -II immunoreactivity was observed in astrocytes in the periventricular area and those around the blood vessels, indicating that MT-I & -II may play a role as a barrier against the toxic substances including metals. MT-I & -II positive astrocytes were also predominant in the brain regions with severe age-related changes, such as neuronal loss and axonal dystrophy. Therefore, MT-I & -II may play an important role in the protection of the brain tissue from the toxic insults responsible for the brain aging.
As to the role of MT-III, maintenance of Zn-related essential functions of the brain has been reported based on the study of the spatio-temporal pattern of MT-III gene expression in the brain of mice [12] . Predominant and consistent expression of MT-III was also shown in neurons in the Zn-rich regions such as hippocampus and parahippocampus in the brain of dogs. Both MT-III immunoreactivity and signals for MT-III mRNA were demonstrated in neurons in the brain of dogs regardless of the intensity of the age-related changes. Further study is required for the elucidation of detailed functions of MT-III in the brain.
